Rybelsus for weight loss: what the new NEJM data actually shows

What did @dr_cristianortiz actually say?

Honestly? It's hard to tell. The transcript from this video is largely incoherent, a string of fragmented sentences about unnamed people traveling between unnamed countries and holding unnamed government positions. There is no discernible medical claim in the spoken content. What we do have is a caption referencing Rybelsus and a direct link to a 2025 NEJM study on oral semaglutide. So the fact-check here is really about what that study says, and whether the framing in the caption is accurate.

The caption asks "¿Rybelsus para bajar de peso?" which translates to "Rybelsus for weight loss?" This is a legitimate clinical question. Rybelsus (oral semaglutide 3mg, 7mg, 14mg) is FDA-approved for type 2 diabetes, not obesity. The NEJM study linked appears to be evaluating higher doses for weight management. That distinction matters enormously, and the caption does nothing to make it.

Does the science back this up?

The linked NEJM study, published in 2025, is the most relevant piece of evidence here. Higher-dose oral semaglutide does appear to produce meaningful weight loss, but the effect size and the approved indication still need separating. The short answer is: yes, there is emerging data supporting oral semaglutide for weight management, but the drug is not currently approved for that use in the United States.

The 2025 NEJM paper (DOI: 10.1056/NEJMoa2500969) evaluated oral semaglutide at doses higher than those currently approved, specifically in people with overweight or obesity. Early phase data from the OASIS trials and related work by Knop et al. (2023, NEJM) demonstrated that oral semaglutide at 50mg produced roughly 15% body weight reduction over 68 weeks. That is competitive with injectable GLP-1 data, which is a meaningful development. However, gastrointestinal side effects were substantial, and the bioavailability challenges of oral semaglutide make consistent dosing more complicated than the injectable formulations.

What did they get wrong (or right)?

The creator did not get anything technically wrong in the spoken content, because the spoken content said essentially nothing medically useful. That is its own problem. Linking a complex NEJM study without explaining it, under a vague caption aimed at weight-loss-curious Spanish-speaking viewers, is not education. It is the appearance of education.

What the caption implies, without stating, is that Rybelsus is a weight loss drug you could take. That framing skips several important facts. Rybelsus at currently approved doses (up to 14mg) produces far more modest weight loss than Wegovy or Mounjaro. The 2025 NEJM data involves investigational higher doses not yet approved. Patients who see this and ask their doctor about "Rybelsus for weight loss" may be prescribed an off-label dose or, more likely, told the drug is not indicated for obesity, walking away confused. The gap between the study and the social media framing is the problem here.

What should you actually know?

If you are researching GLP-1 options for weight management, oral semaglutide at approved doses is not your strongest option right now. Here is what the actual data landscape looks like as of mid-2025.

• Wegovy (subcutaneous semaglutide 2.4mg weekly) is FDA-approved for chronic weight management and produced approximately 15% mean body weight loss in the STEP 1 trial (Wilding et al., 2021, NEJM).
• Zepbound (tirzepatide) is FDA-approved for obesity and produced up to 20.9% mean weight loss in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM).
• Oral semaglutide at investigational 50mg doses showed approximately 15% weight loss in the OASIS 1 trial (Knop et al., 2023, NEJM), but this dose is not approved.
• Rybelsus at approved doses (up to 14mg) was not designed or powered as a weight loss drug. Using it for weight loss off-label at standard doses is likely to produce underwhelming results compared to injectable alternatives.

If you are considering any GLP-1 medication for weight management, the conversation needs to happen with a licensed prescriber who can evaluate your full medical history, not a TikTok caption with a journal link.